High-dose linaclotide is effective and safe in patients with chronic constipation: A phase III randomized, double-blind, placebo-controlled study with a long-term open-label extension study in Japan.
Shin FukudoHiroto MiwaAtsushi NakajimaYoshikazu KinoshitaMasanori KosakoKenta HayashiHiraku AkihoKentaro KuroishiJeffrey M JohnstonMark CurrieToshifumi OhkusaPublished in: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society (2018)
The results of this study indicate that a linaclotide dose of 0.5 mg/day is effective and safe in Japanese CC patients.
Keyphrases
- phase iii
- double blind
- open label
- placebo controlled
- clinical trial
- phase ii
- high dose
- end stage renal disease
- study protocol
- ejection fraction
- phase ii study
- newly diagnosed
- chronic kidney disease
- randomized controlled trial
- peritoneal dialysis
- squamous cell carcinoma
- stem cell transplantation
- radiation therapy
- irritable bowel syndrome
- rectal cancer